Rating Change
Roth Capital analysts initiated coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a rating of Buy on October 27, 2026.
new coverageNASDAQ:DNTH
Roth Capital Initiates Coverage on Dianthus Therapeutics, Inc. (DNTH) with Buy
Roth Capital analysts initiated coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a rating of Buy on October 27, 2026.
At publication ·
What changed
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) · new coverage
- Firm
- Roth Capital
- Rating
- Buy
- Price at event
- $79.34
- Market capitalization
- $1.5B
At a glance
Key takeaways
- Roth Capital initiated Buy coverage on Dianthus Therapeutics (DNTH) on October 27, 2026, as the healthcare company trades at $79.34 with a $1.5B market capitalization.
Market Context
Dianthus Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $79.34 with a market capitalization of $1.5B.
Analyst coverage from Roth Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Dianthus Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Dianthus Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 27, 2026 | Roth Capital | Buy | N/A |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 11, 2026 | JP Morgan | Overweight | N/A |
| Sep 04, 2026 | Citigroup | Buy | N/A |
| Aug 06, 2026 | Truist Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View DNTH Stock Page
Frequently Asked Questions
What does the Buy rating mean for DNTH?
A rating of Buy from Roth Capital reflects the analyst's outlook on Dianthus Therapeutics, Inc. (NASDAQ:DNTH). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the DNTH forecast page.